Merck patents expiration
1. Cancidas patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5378804 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(11 years ago) | |
| US5792746 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(11 years ago) | |
|
US5378804 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(10 years ago) | |
|
US5792746 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(10 years ago) | |
| US5514650 | MERCK | Aza cyclohexapeptide compounds |
Jan, 2015
(9 years ago) | |
|
US5514650 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Jul, 2015
(8 years ago) | |
| US5952300 | MERCK | Antifungal compositions |
Mar, 2017
(7 years ago) | |
| US6136783 | MERCK | Antifungal compositions |
Mar, 2017
(7 years ago) | |
|
US6136783 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(6 years ago) | |
|
US5952300 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(6 years ago) | |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 26 January, 2001
Treatment: Cancidas is indicated for empirical therapy for presumed fungal infections in febrile, neutropenic patients.
Dosage: POWDER;INTRAVENOUS
CANCIDAS family patents
2. Emend patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214692 | MERCK | Medical use for tachykinin antagonists |
Sep, 2012
(11 years ago) | |
| US5538982 | MERCK | Medical use for tachykinin antagonists |
Jul, 2013
(10 years ago) | |
| US5719147 | MERCK | Morpholine and thiomorpholine tachykinin receptor antagonists |
Apr, 2015
(9 years ago) | |
| US6096742 | MERCK | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(5 years ago) | |
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 28, 2018 |
| M(M-82) | Mar 19, 2013 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 30 June, 2006
Treatment: Treatment or prevention of emesis; Prevention of postoperative nausea and vomiting
Dosage: CAPSULE;ORAL
EMEND family patents
3. Fosamax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5462932 | MERCK | Oral liquid alendronate formulations |
May, 2014
(9 years ago) | |
|
US5462932 (Pediatric) | MERCK | Oral liquid alendronate formulations |
Nov, 2014
(9 years ago) | |
| US5994329 | MERCK | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6015801 | MERCK | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6225294 | MERCK | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
|
US6015801 (Pediatric) | MERCK | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US5994329 (Pediatric) | MERCK | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6225294 (Pediatric) | MERCK | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
Drugs and Companies using ALENDRONATE SODIUM ingredient
Market Authorisation Date: 17 September, 2003
Treatment: NA
Dosage: SOLUTION;ORAL
FOSAMAX family patents
4. Vioxx patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5474995 | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Jun, 2013
(10 years ago) | |
| US6239173 | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Jun, 2013
(10 years ago) | |
|
US6239173 (Pediatric) | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Dec, 2013
(10 years ago) | |
|
US5474995 (Pediatric) | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Dec, 2013
(10 years ago) | |
| US5691374 | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
May, 2015
(8 years ago) | |
|
US5691374 (Pediatric) | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
Nov, 2015
(8 years ago) | |
| US6063811 | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
May, 2017
(6 years ago) | |
|
US6063811 (Pediatric) | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
Nov, 2017
(6 years ago) | |
Drugs and Companies using ROFECOXIB ingredient
Market Authorisation Date: 20 May, 1999
Treatment: Relief of the signs and symptoms of osteoarthritis; Relief of the signs and symptoms of rheumatoid arthritis in adults; Management of acute pain in adults; Treatment of primary dysmenorrhea; Acute tre...
Dosage: TABLET;ORAL; SUSPENSION;ORAL
VIOXX family patents